JP2024529533A - Ｅｒｂｂおよびｂｔｋ阻害剤の新規な医薬塩および多形形態 - Google Patents

Ｅｒｂｂおよびｂｔｋ阻害剤の新規な医薬塩および多形形態 Download PDF

Info

Publication number
JP2024529533A
JP2024529533A JP2024506641A JP2024506641A JP2024529533A JP 2024529533 A JP2024529533 A JP 2024529533A JP 2024506641 A JP2024506641 A JP 2024506641A JP 2024506641 A JP2024506641 A JP 2024506641A JP 2024529533 A JP2024529533 A JP 2024529533A
Authority
JP
Japan
Prior art keywords
crystalline form
compound
egfr
xrpd pattern
degrees
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024506641A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024529533A5 (https=
Inventor
チェン，ジュン－チェン
ジアン，ジャナン
グオ，チンハイ
チャン，シー－イン
ゼン，チンベイ
ツイ，ホンチュン
ヤン，チェンファン
チャン，シャオリン
Original Assignee
ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド filed Critical ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド
Publication of JP2024529533A publication Critical patent/JP2024529533A/ja
Publication of JP2024529533A5 publication Critical patent/JP2024529533A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/185—Saturated compounds having only one carboxyl group and containing keto groups
    • C07C59/225—Saturated compounds having only one carboxyl group and containing keto groups containing —CHO groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024506641A 2021-08-02 2022-07-29 Ｅｒｂｂおよびｂｔｋ阻害剤の新規な医薬塩および多形形態 Pending JP2024529533A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2021110048 2021-08-02
CNPCT/CN2021/110048 2021-08-02
PCT/CN2022/109065 WO2023011358A1 (en) 2021-08-02 2022-07-29 Novel pharmaceutical salts and polymorphic forms of an erbb and btk inhibitor

Publications (2)

Publication Number Publication Date
JP2024529533A true JP2024529533A (ja) 2024-08-06
JP2024529533A5 JP2024529533A5 (https=) 2025-08-06

Family

ID=85154265

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024506641A Pending JP2024529533A (ja) 2021-08-02 2022-07-29 Ｅｒｂｂおよびｂｔｋ阻害剤の新規な医薬塩および多形形態

Country Status (11)

Country Link
US (1) US20250197377A1 (https=)
EP (1) EP4380924A4 (https=)
JP (1) JP2024529533A (https=)
KR (1) KR20240042640A (https=)
CN (1) CN117794902A (https=)
AR (1) AR126673A1 (https=)
AU (1) AU2022324410A1 (https=)
CA (1) CA3224748A1 (https=)
MX (1) MX2024001367A (https=)
TW (1) TW202321223A (https=)
WO (1) WO2023011358A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4731307A1 (en) 2023-06-23 2026-04-29 Assia Chemical Industries Ltd. Solid state forms of sunvozertinib

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015510890A (ja) * 2012-03-15 2015-04-13 セルジーン アヴィロミクス リサーチ， インコーポレイテッド 上皮成長因子受容体キナーゼ阻害剤の塩
CN105384694A (zh) * 2014-08-22 2016-03-09 四川海思科制药有限公司 一种取代的氨基嘧啶衍生物及其制备方法和药物用途
CN106083736A (zh) * 2016-06-21 2016-11-09 郑州泰基鸿诺医药股份有限公司 一种嘧啶类化合物、egfr抑制剂及其应用
CN106905245A (zh) * 2015-12-23 2017-06-30 正大天晴药业集团股份有限公司 2,4-二取代的嘧啶类化合物
WO2019177375A1 (ko) * 2018-03-13 2019-09-19 포로노이바이오 주식회사 2, 4, 5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
JP2021512087A (ja) * 2018-01-31 2021-05-13 ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド Ｅｒｂｂ／ｂｔｋ阻害剤

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015510890A (ja) * 2012-03-15 2015-04-13 セルジーン アヴィロミクス リサーチ， インコーポレイテッド 上皮成長因子受容体キナーゼ阻害剤の塩
CN105384694A (zh) * 2014-08-22 2016-03-09 四川海思科制药有限公司 一种取代的氨基嘧啶衍生物及其制备方法和药物用途
CN106905245A (zh) * 2015-12-23 2017-06-30 正大天晴药业集团股份有限公司 2,4-二取代的嘧啶类化合物
CN106083736A (zh) * 2016-06-21 2016-11-09 郑州泰基鸿诺医药股份有限公司 一种嘧啶类化合物、egfr抑制剂及其应用
JP2021512087A (ja) * 2018-01-31 2021-05-13 ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド Ｅｒｂｂ／ｂｔｋ阻害剤
WO2019177375A1 (ko) * 2018-03-13 2019-09-19 포로노이바이오 주식회사 2, 4, 5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
平山 令明, 有機化合物結晶作製ハンドブック −原理とノウハウ−, JPN6021045084, 2008, pages 36 - 43, ISSN: 0005834981 *
芦澤 一英 他, 医薬品の多形現象と晶析の科学, JPN7015003233, 2002, pages 305 - 317, ISSN: 0005834979 *
芦澤 一英: "塩・結晶形の最適化と結晶化技術", PHARM TECH JAPAN, vol. 18, no. 10, JPN6013060608, 2002, pages 81 - 96, ISSN: 0005834982 *
長瀬 博, 最新 創薬化学 下巻, JPN6016015442, 1999, pages 347 - 354, ISSN: 0005834980 *

Also Published As

Publication number Publication date
WO2023011358A1 (en) 2023-02-09
US20250197377A1 (en) 2025-06-19
CN117794902A (zh) 2024-03-29
KR20240042640A (ko) 2024-04-02
EP4380924A4 (en) 2025-10-01
MX2024001367A (es) 2024-02-27
CA3224748A1 (en) 2023-02-09
TW202321223A (zh) 2023-06-01
AR126673A1 (es) 2023-11-01
EP4380924A1 (en) 2024-06-12
AU2022324410A1 (en) 2024-01-18

Similar Documents

Publication Publication Date Title
JP7834584B2 (ja) （Ｓ）－４－（８－アミノ－３－（１－（ブト－２－イノイル）ピロリジン－２－イル）イミダゾ［１，５－ａ］ピラジン－１－イル）－Ｎ－（ピリジン－２－イル）ベンザミドの固体形態及び製剤
TW202519524A (zh) 固態形式
EP2643314B1 (en) Novel salts and polymorphic forms of afatinib
TW202110836A (zh) 固態形式
US12084431B2 (en) Pharmaceutical salts of pyrimidine derivatives and method of treating disorders
AU2013245878A1 (en) Salt form of a human histone methyltransferase EZH2 inhibitor
JP7492742B2 (ja) 置換ジアミノ複素環式カルボキサミド化合物、該化合物を含む組成物およびその使用
IL298132A (en) Salt and crystal forms of 4-amino-5-(6-(4-methylpiperazin-1-yl)-1h-benzo[d]imidazol-2-yl)thieno[2,3-b]pyridin-6(7h)-one
KR100687165B1 (ko) 결정성 2,5-디온-3-(1-메틸-1ｈ-인돌-3-일)-4-[1-[1-(피리딘-2-일메틸)피페리딘-4-일]-1ｈ-인돌-3-일]-1ｈ-피롤 모노-하이드로클로라이드
JP2024529533A (ja) Ｅｒｂｂおよびｂｔｋ阻害剤の新規な医薬塩および多形形態
HK40109564A (zh) Erbb和btk抑制剂的新型药用盐和多晶型形式
TW202311267A (zh) 咪唑烷酮類化合物的多晶型物、包含其的藥物組合物、其製備方法及其應用
EP2975035B1 (en) Salt of pyrrolidin-3-yl acetic acid derivative and crystals thereof
WO2018115965A1 (en) Solid forms of imidazopyrazine compounds
KR20250170660A (ko) 퀴나졸린 erbb 억제제의 약학적 형태
TW202342041A (zh) 一種藥物組合物及所含活性成分化合物的製備方法
HK40126640A (zh) 喹唑啉erbb抑制剂的药物形式
HK40096550A (en) Pharmaceutical salts of pyrimidine derivatives and method of treating disorders
WO2023230968A1 (zh) Shp2抑制剂、其晶型及其制备方法与用途
HK40072166B (zh) 杂环化合物及其制备方法和用途
KR20210050530A (ko) 신규 아자트리시클릭 화합물의 염 형태 및 결정 형태 및 그의 용도
HK40042843A (en) Salt form and crystal form of novel azatricyclic compound and use thereof
HK40026825A (en) Salt form for ezh2 inhibition

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250729

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250729

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260407